Letter: Breaking new ground—Understanding the role of <scp>ATI</scp>‐free diet in managing <scp>MASLD</scp>

Letter: Breaking new ground—Understanding the role of ATI‐free diet in managing MASLD—Authors' reply

Published:2024-06-11 Issue:2 Volume:60 Page:304-305
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Armandi Angelo¹²^ORCID,Schuppan Detlef³⁴^ORCID,Schattenberg Jörn M.²⁵

Affiliation:

1. Division of Gastroenterology and Hepatology, Department of Medical Sciences University of Turin Turin Italy

2. Metabolic Liver Disease Research Program, I. Department of Medicine University Medical Center of the Johannes Gutenberg‐University Mainz Germany

3. University Medical Center, Institute of Translational Immunology and Research Center for Immunotherapy Johannes Gutenberg‐University Mainz Germany

4. Division of Gastroenterology, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA

5. Department of Internal Medicine II Saarland University Medical Center Homburg Germany

Abstract

LINKED CONTENTThis article is linked to Armandi et al papers. To view these articles, visit https://doi.org/10.1111/apt.17941 and https://doi.org/10.1111/apt.18064

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18119

Reference9 articles.

1. SpertinoM RossiRE PuglieseN.Letter: Breaking new ground—understanding the role of ATI‐free diet in managing MASLD. Aliment Pharmacol Ther.2024;60:302–303.

2. Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study

3. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes

4. Gut-liver axis: Pathophysiological concepts and clinical implications